<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-128790</identifier>
<setSpec>0365-6691</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Polyalkylimide filler in human immunodeficiency virus-associated facial lipodystrophy: ophthalmic complications</dc:title>
<dc:description xml:lang="en">Case report: A 54 year old male, who consulted for acute inflammatory palpebral edema. The patient has HIV infection (on antiretroviral treatment) and an associated facial lipodystrophy that was filled with polyalkylimide in both frontotemporal regions one year before. MRI revealed subcutaneous abscesses in the filled areas, which led to preseptal cellulitis. Complete remission was achieved with antibiotic therapy and monitoring. Discussion: Polyalkylimide is a hydrogel that is recently used as facial filler without FDA approval. Although it was believed to be safe and useful for treating HIV lipodystrophy, it is not exempt from adverse effects (infection, abscesses, granulomas) that can compromise the eye area (AU)</dc:description>
<dc:creator>Campos-García, S</dc:creator>
<dc:creator>Blanco-Rivas, R</dc:creator>
<dc:creator>García-Pacheco, S. A</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Caso clínico: Varón de 54 años, quien consulta por edema palpebral inflamatorio agudo. Tiene infección por VIH en tratamiento antirretroviral y una lipodistrofia facial asociada que se rellenó un año antes con polialquilamida en ambas regiones frontotemporales. La RMN reveló abscesos subcutáneos en áreas de relleno, que condicionaron una celulitis preseptal. Se consiguió remisión total con antibioterapia y seguimiento. Discusión: La polialquilamida es un hidrogel que se usa recientemente como relleno facial, sin aprobación de la FDA. Aunque se creía segura y útil para tratar la lipodistrofia asociada al VIH, no está exenta de efectos adversos (infección, abscesos, granulomas) que pueden comprometer el área oftalmológica (AU)</dc:description>
<dc:source>Arch Soc Esp Oftalmol;89(10): 421-424, oct. 2014. ilus</dc:source>
<dc:identifier>ibc-128790</dc:identifier>
<dc:title xml:lang="es">Rellenos de polialquilamida en lipodistrofia facial asociada al virus de la inmunodeficiencia humana: complicaciones oftalmológicas</dc:title>
<dc:subject>^d29416^s22011</dc:subject>
<dc:subject>^d3252^s22005</dc:subject>
<dc:subject>^d15182^s22044</dc:subject>
<dc:subject>^d15182^s22011</dc:subject>
<dc:subject>^d3252^s22044</dc:subject>
<dc:subject>^d29416</dc:subject>
<dc:subject>^d15182^s22038</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d3252^s22009</dc:subject>
<dc:type>article</dc:type>
<dc:date>201410</dc:date>
</metadata>
</record>
</ibecs-document>
